AC Immune Q1 net loss narrows on lower expenses

Overview

• Switzerland biopharma firm's Q1 net loss narrowed yr/yr on lower R&D and G&A expenses

• Company ended Q1 with CHF 74.8 mln in cash, funding expected into Q4 2027

Outlook

• Company expects interim results from ABATE Phase 2 ACI-24 trial in H1 2026

• Company expects final data from Part 1 of ACI-7104 Phase 2 VacSYn trial in H2 2026

Result Drivers

• LOWER R&D AND G&A SPEND - Co said reduced R&D and G&A expenses contributed to narrower net loss in Q1

• PIPELINE FOCUS INITIATIVES - Co attributed lower R&D spend to pipeline focus initiatives announced in Q3 2025

Company press release: ID:nGNX9K8xTQ

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for AC Immune SA is $8.50, about 190.1% above its April 29 closing price of $2.93

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.